This review concluded that angioplasty is superior to thrombolysis for 1-month fatal and nonfatal outcomes in patients with non-ST myocardial infarction where the time delay is 30 to 90 minutes. The conclusions appear reliable, but consideration should be given to the poor reporting of review methods and the authors' own cautions and limitations.
Study selection
Randomised controlled trials (RCTs) comparing intravenous thrombolysis and primary angioplasty using any type of drug, in patients with ST elevation myocardial infarction, were eligible for inclusion. The majority of the included trials used plasminogen activator for thrombolysis and coronary stents for angioplasty. Eligible studies had to report one of the following outcomes of interest: mortality, nonfatal infarctions and fatal, nonfatal and haemorrhagic strokes, in addition to any data about delays in treatment. All trials reported outcomes at between 30 days and 6 weeks (referred to as 1-month outcomes in the analysis), while just less than half of the trials reported outcomes at 6 months postintervention. Few included studies reported the number of fatal or haemorrhagic strokes at 6 months post-intervention.
The authors did not state how the papers were selected for the review, or how many reviewers performed the selection.
Assessment of study quality
The authors did not state that they assessed validity.
Data extraction
Two reviewers independently extracted the data from the included studies. Any discrepancies were resolved through consensus, with a third reviewer consulted if necessary. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for the incidences of death, nonfatal infarctions and nonfatal strokes at 1 and 6 months post-intervention, using intention-to-treat data. The mean times and standard deviations (SDs) to treatment were also extracted; medians and quartiles were used where means and SDs were not available.
The benefit of primary angioplasty, over thrombolysis, depends on the additional time delay for angioplasty. Angioplasty is superior to thrombolysis for 1-month fatal and nonfatal outcomes where the time delay is 30 to 90 minutes. Where the time delay is around 90 minutes thrombolysis may be preferable, as assessed by 6-month mortality, but longer time delays are subject to considerable uncertainty.
CRD commentary
This review updates a previous review. It answered a clear review question, searching a number of electronic databases. However, it is difficult to assess the reliability of the authors' methods without further details of the review process. The lack of any assessment of study validity, publication bias, statistical and clinical heterogeneity, and the influence of individual studies also hinders any assessment of the reliability of the data. However, the authors used Bayesian methods to assess the size of effect and its relationship to time delay, which also incorporated a sensitivity analysis to determine the effect of uncertainty around input parameters (prior distributions) in the analysis. The authors identified a number of cautions and limitations concerning, amongst others, the reliability of the data on longer delays and the applicability of the findings to other populations. In conclusion, the data presented appears to support the review findings, but consideration should be given to the poor reporting of review methods and the authors' own cautions and limitations.
Implications of the review for practice and research
Practice: The authors stated that 'if primary angioplasty can be delivered in a appropriate fashion, current evidence supports its use; if not, the choice of treatment probably depends on time from onset of symptoms to presentation and the availability of pre-hospital thrombolysis'. They also stated that the decision about appropriate methods of reperfusion should also take into account the cost-effectiveness of each treatment option.
Research: The authors stated that it would be advisable to investigate whether the potential relationship between time delay and effect in terms of log ORs is linear. They also highlighted the lack of data about the effects of long-term delays in angioplasty.
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